Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Delays CERA Oncology Filing Until 2009

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche is pushing back the timeline for filing its anti-anemia drug CERA, its continuous erythropoietin receptor activator, for the treatment of chemotherapy-associated anemia until 2009, the company reported Feb. 1

You may also be interested in...



Roche Suspends Phase II Mircera Study In Chemo-Induced Anemia

Firm halts recruitment of anemic non-small cell lung cancer patients due to an “imbalance” of deaths across study arms but maintains they are not related to the drug.

Roche Suspends Phase II Mircera Study In Chemo-Induced Anemia

Firm halts recruitment of anemic non-small cell lung cancer patients due to an “imbalance” of deaths across study arms but maintains they are not related to the drug.

Amgen Will Have Day In Court With Roche

The company also reports that sales of its TNF inhibitor Enbrel are “not meeting expectations.”

Related Content

Topics

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel